Drugs that contain Lonafarnib
1. Zokinvy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7838531 | EIGER BIOPHARMS | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
Jul, 2024
(3 months from now) | |
| US8828356 | EIGER BIOPHARMS | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
Oct, 2024
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-324) | Nov 20, 2027 |
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2025 |
NCE-1 date: 20 November, 2024
Market Authorisation Date: 20 November, 2020
Treatment: Reducing the risk of mortality in hutchinson-gilford progeria syndrome (hgps)
Dosage: CAPSULE;ORAL
More Information on Dosage
ZOKINVY family patents
